Schedule 13G ownership disclosure

Rigel Pharmaceuticals Inc

Common Stock, $0.001 par value per share · CUSIP: 766559702

Event date: 2025-06-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Soleus Capital Master Fund, L.P.

    Shares: 658,145.00 · Class: 3.7%

  • Soleus Capital, LLC

    Shares: 658,145.00 · Class: 3.7%

  • Soleus Capital Group, LLC

    Shares: 658,145.00 · Class: 3.7%

  • Soleus Capital Management, L.P.

    Shares: 658,145.00 · Class: 3.7%

  • Soleus GP, LLC

    Shares: 658,145.00 · Class: 3.7%

  • Guy Levy

    Shares: 658,145.00 · Class: 3.7%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001213900-25-072157
Form type
SCHEDULE 13G/A
Filer
RIGEL PHARMACEUTICALS INC
CIK
CIK 1034842
Filed
Aug 05, 2025
Reporting period
Jun 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub